Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba  

作　　者：Weile Ye Jiaojiao Wang Peter JLittle Jiami Zou Zhihua Zheng Jing Lu Yanjun Yin Hao Liu Dongmei Zhang Peiqing Liu Suowen Xu Wencai Ye Zhiping Liu 

机构地区：[1]International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education(MOE)of China,Jinan University,Guangzhou 510632,China [2]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research,College of Pharmacy,Jinan University,Guangzhou 510632,China [3]State Key Laboratory of Bioactive Molecules and Druggability Assessment,Jinan University,Guangzhou 510632,China [4]Pharmacy Australia Centre of Excellence,School of Pharmacy,University of Queensland,Woolloongabba QLD 4102,Australia [5]Sunshine Coast Health Institute and School of Health and Behavioural Sciences,University of the Sunshine Coast,Birtinya QLD 4575,Australia [6]National-Local Joint Engineering Lab of Druggability and New Drugs Evaluation,Guangdong Provincial Key Laboratory of New Drug Design and Evaluation,Sun Yat-sen University,Guangzhou 510006,China [7]School of Pharmacy,Bengbu Medical College,Bengbu 233030,China [8]Institute of Endocrine and Metabolic Diseases,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230026,China

出　　处：《Acta Pharmaceutica Sinica B》2024年第1期1-19,共19页药学学报（英文版）

基　　金：This work is supported by National Natural Science Foundation of China(82270500,81870324,82203304,82070464,U1401225,U21A20419);National Mega-Project for Innovative Drugs(2019ZX09735002);Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program(2017BT01Y036,2017BT01Y093,China);National Engineering and Technology Research Center for New drug Druggability Evaluation(Seed Program of Guangdong Province,2017B090903004,China).

摘　　要：Bioactive compounds derived from herbal medicinal plants modulate various therapeutic targets and signaling pathways associated with cardiovascular diseases(CVDs),the world’s primary cause of death.Ginkgo biloba,a well-known traditional Chinese medicine with notable cardiovascular actions,has been used as a cardio-and cerebrovascular therapeutic drug and nutraceutical in Asian countries for centuries.Preclinical studies have shown that ginkgolide B,a bioactive component in Ginkgo biloba,can ameliorate atherosclerosis in cultured vascular cells and disease models.Of clinical relevance,several clinical trials are ongoing or being completed to examine the efficacy and safety of ginkgolide B-related drug preparations in the prevention of cerebrovascular diseases,such as ischemia stroke.Here,we present a comprehensive review of the pharmacological activities,pharmacokinetic characteristics,and mechanisms of action of ginkgolide B in atherosclerosis prevention and therapy.We highlight new molecular targets of ginkgolide B,including nicotinamide adenine dinucleotide phosphate oxidases(NADPH oxidase),lectin-like oxidized LDL receptor-1(LOX-1),sirtuin 1(SIRT1),platelet-activating factor(PAF),proprotein convertase subtilisin/kexin type 9(PCSK9)and others.Finally,we provide an overview and discussion of the therapeutic potential of ginkgolide B and highlight the future perspective of developing ginkgolide B as an effective therapeutic agent for treating atherosclerosis.

关 键 词：Cardiovascular disease Atherosclerosis Ginkgo biloba Ginkgolide B Endothelial dysfunction LOX-1 PCSK9 PAF-R antagonist 

分 类 号：R96[医药卫生—药理学] R543[医药卫生—药学]